This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donoghue, S. Articles by Pringle, J. H. Search for Related Content PubMed PubMed Citation Articles by Donoghue, S. Articles by Pringle, J. H.

Immunohistochemical Localization of Caspase-3 Correlates with Clinical Outcome in B-Cell Diffuse Large-Cell Lymphoma¹

Departments of Pathology [S. D., I. L., J. H. P.] and Haematology [H. S. B.], Robert Kilpatrick Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, United Kingdom, and Department of Haematology, Boston Pilgrim Hospital, Lincolnshire PE21 9QS, United Kingdom [S. S.]

Although B-cell diffuse large-cell lymphoma (DLCL) can respond to chemotherapy and radiotherapy, a large number of patients are still resistant to treatment. Caspase-3 is an enzyme crucial to the apoptotic process and may be important in the clinical outcome of these patients. The pattern of caspase-3 expression was studied in 54 cases of DLCL using immunohistochemistry and quantitative reverse-transcription PCR. Tumor cells displayed both a diffuse cytosolic and a punctate cytosolic staining for caspase-3. Kaplan-Meier survival curves indicated that tumor cells with a diffuse cytosolic expression of caspase-3 correlated with a poor prognosis (P > 0.0004). In addition, a punctate cellular localization was associated with complete response to treatment (P = 0.011). Cases with a small percentage of lymphoma cells expressing caspase-3 also tended to show poor survival (P > 0.09). Levels of caspase-3mRNA were not significant (P > 0.17), although a weak trend was observed similar to the immunohistochemical analysis. The pattern of expression of caspase-3 was also assessed with respect to terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) positivity in both reactive lymph nodes and B-cell DLCL cases. Our results suggest that TUNEL-positive cells are not caspase-3-positive and that there is no correlation between DLCL cases with a high degree of DNA fragmentation and caspase-3 immunostaining. Furthermore, a survival curve indicated that a high TUNEL positivity was associated with a poor survival probability (P < 0.02) and a poor response to treatment (P = 0.04). These results confirm the dynamic nature of caspase-3 expression in DLCL and suggests that the pattern of expression of the enzyme has prognostic significance.

This article has been cited by other articles:

				T. Kobayashi, J. Masumoto, T. Tada, T. Nomiyama, K. Hongo, and J. Nakayama Prognostic Significance of the Immunohistochemical Staining of Cleaved Caspase-3, an Activated Form of Caspase-3, in Gliomas Clin. Cancer Res., July 1, 2007; 13(13): 3868 - 3874. [Abstract] [Full Text] [PDF]

				R. N. Winter, A. Kramer, A. Borkowski, and N. Kyprianou Loss of Caspase-1 and Caspase-3 Protein Expression in Human Prostate Cancer Cancer Res., February 1, 2001; 61(3): 1227 - 1232. [Abstract] [Full Text]